Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

R. G. Langley; K. Papp; A. B. Gottlieb; G. G. Krueger; K. B. Gordon; D. Williams; J. Valdes; C. Setze; B. Strober

doi:10.1111/j.1468-3083.2012.04705.x

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

R. G. Langley, K. Papp, A. B. Gottlieb, G. G. Krueger, K. B. Gordon, D. Williams, J. Valdes, C. Setze, B. Strober

Inernational Relations Division

科研成果: 期刊稿件 › 文章 › 同行评审

59 引用（Scopus）

源语言	英语
页（从-至）	1252-1261
页数	10
期刊	Journal of the European Academy of Dermatology and Venereology
卷	27
期	10
DOI	https://doi.org/10.1111/j.1468-3083.2012.04705.x
出版状态	已出版 - 10月 2013

!!!ASJC Scopus Subject Areas

皮肤医学
传染病学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1111/j.1468-3083.2012.04705.x

其它文件与链接

指纹

探究 'Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis' 的科研主题。它们共同构成独一无二的指纹。

引用此

Langley, R. G., Papp, K., Gottlieb, A. B., Krueger, G. G., Gordon, K. B., Williams, D., Valdes, J., Setze, C., & Strober, B. (2013). Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 27(10), 1252-1261. https://doi.org/10.1111/j.1468-3083.2012.04705.x

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. / Langley, R. G.; Papp, K.; Gottlieb, A. B. 等.
在: Journal of the European Academy of Dermatology and Venereology, 卷 27, 号码 10, 10.2013, 页码 1252-1261.

科研成果: 期刊稿件 › 文章 › 同行评审

Langley, RG, Papp, K, Gottlieb, AB, Krueger, GG, Gordon, KB, Williams, D, Valdes, J, Setze, C & Strober, B 2013, 'Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis', Journal of the European Academy of Dermatology and Venereology, 卷 27, 号码 10, 页码 1252-1261. https://doi.org/10.1111/j.1468-3083.2012.04705.x

Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D 等. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology. 2013 10月;27(10):1252-1261. doi: 10.1111/j.1468-3083.2012.04705.x

Langley, R. G. ; Papp, K. ; Gottlieb, A. B. 等. / Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. 在: Journal of the European Academy of Dermatology and Venereology. 2013 ; 卷 27, 号码 10. 页码 1252-1261.

@article{f7ea7ea9cf004658b80e84d0970fa53d,

title = "Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis",

author = "Langley, {R. G.} and K. Papp and Gottlieb, {A. B.} and Krueger, {G. G.} and Gordon, {K. B.} and D. Williams and J. Valdes and C. Setze and B. Strober",

year = "2013",

month = oct,

doi = "10.1111/j.1468-3083.2012.04705.x",

language = "English",

volume = "27",

pages = "1252--1261",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell",

number = "10",

}

TY - JOUR

T1 - Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

AU - Langley, R. G.

AU - Papp, K.

AU - Gottlieb, A. B.

AU - Krueger, G. G.

AU - Gordon, K. B.

AU - Williams, D.

AU - Valdes, J.

AU - Setze, C.

AU - Strober, B.

PY - 2013/10

Y1 - 2013/10

UR - http://www.scopus.com/inward/record.url?scp=84884900971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884900971&partnerID=8YFLogxK

U2 - 10.1111/j.1468-3083.2012.04705.x

DO - 10.1111/j.1468-3083.2012.04705.x

M3 - Article

C2 - 23157612

AN - SCOPUS:84884900971

SN - 0926-9959

VL - 27

SP - 1252

EP - 1261

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 10

ER -